A Multicenter Phase 3 Randomized, Open-Label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogeno
Posted Date: May 15, 2019
- Investigator: Zartash Gul
- Specialties: Leukemia, Oncology
- Type of Study: Drug
This study is designed to obtain information on the safety and the effectiveness of an experimental drug called bosutinib as the first treatment of CML. Bosutinib is being compared to treatment with another drug called imatinib. Imatinib has been approved for the treatment of patients with newly dia
Criteria:
To Be Eligible For This Study, Patients Must Be Newly Diagnosed With Chronic Myelogenous Leukemia (C
Keywords:
Leukemia, Av001, Cancer, Chronic Myelogenous , Cml
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com